A molecular model for persister in E. coli

Journal of Theoretical Biology
Chunbo LouQi Ouyang

Abstract

Like many other bacteria, Escherichia coli remain as tiny viable individuals named persisters after being exposed to an antibiotic. These persisters are believed to be phenotypic heterogeneous one rather than mutants, because their progenies are as susceptible to antibiotics as their ancestors. Recently, two persister-related genes (hipB/hipA) were confirmed to belong to a toxin-antitoxin (TA) module. Their control circuit was believed to be responsible for generation of the persister subpopulation. For the well-studied TA module, we build a simple genetic regulation model to explain the phenotypic heterogeneity. We find that a sole double-negative feedback loop is not enough to explain the phenotypic heterogeneity; the cooperation mechanisms in HipB and HipA are indispensable. Moreover, our model illustrates an important persister-related experimental phenomenon: the emergence of the persister depends on the growth rate in continuous culture.

References

Mar 26, 2002·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Hidde de Jong
Jan 22, 2004·FEMS Microbiology Letters·Iris KerenKim Lewis
May 29, 2004·Genetics·Mukund Thattai, Alexander van Oudenaarden
Aug 17, 2004·Science·Nathalie Q BalabanStanislas Leibler
Mar 26, 2005·Science·Nitzan RosenfeldMichael B Elowitz
May 3, 2005·Nature Reviews. Microbiology·Kenn GerdesAnders Løbner-Olesen
Aug 30, 2005·Journal of Theoretical Biology·N G Cogan
Nov 1, 2005·Trends in Biochemical Sciences·Lieven ButsRemy Loris
Dec 5, 2006·Nature Reviews. Microbiology·Kim Lewis
Jan 12, 2007·Current Opinion in Microbiology·Neeraj Dhar, John D McKinney
Nov 3, 2007·Microbiology·I KlapperP S Stewart

❮ Previous
Next ❯

Citations

Jun 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·Rick A Fasani, Michael A Savageau
Jul 4, 2012·Antimicrobial Agents and Chemotherapy·N G CoganKatherine Petty
May 16, 2013·PloS One·Pintu Patra, Stefan Klumpp
Dec 18, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jingchen FengHerbert Levine
May 20, 2011·Current Opinion in Biotechnology·Matthew Scott, Terence Hwa
Nov 5, 2011·Current Opinion in Genetics & Development·N Q Balaban
Jul 7, 2011·Biotechnology Advances·Lei PeiWei Wei
Jun 13, 2015·Journal of the Royal Society, Interface·Rick A Fasani, Michael A Savageau
Apr 29, 2014·Cell·Etienne Maisonneuve, Kenn Gerdes
Jul 31, 2013·Mathematical Biosciences·N G Cogan
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Eitan RotemNathalie Q Balaban
Mar 24, 2017·FEMS Microbiology Reviews·Bram Van den BerghJan Michiels
Feb 12, 2010·Physical Biology·Yan FuJianhua Xing
Feb 23, 2019·PloS One·Stefan VetLendert Gelens
Sep 11, 2019·Annual Review of Microbiology·Bridget GollanSophie Helaine
Sep 1, 2017·Nucleic Acids Research·Chengzhe TianNamiko Mitarai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.